Mirati Therapeutics Inc. (NASDAQ:MRTX) has been given an average recommendation of “Buy” by the ten brokerages that are covering the firm. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $15.83.

A number of equities analysts have issued reports on the stock. Avondale Partners cut shares of Mirati Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday. HC Wainwright assumed coverage on shares of Mirati Therapeutics in a research note on Thursday. They issued a “buy” rating and a $12.00 price objective on the stock. Leerink Swann reaffirmed a “hold” rating and issued a $7.00 price objective on shares of Mirati Therapeutics in a research note on Friday, November 11th. Zacks Investment Research raised shares of Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a research note on Wednesday, November 9th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $12.00 price objective on shares of Mirati Therapeutics in a research note on Friday, November 4th.

A number of large investors have recently modified their holdings of MRTX. Aviva Holdings Ltd. raised its stake in shares of Mirati Therapeutics by 195.9% in the first quarter. Aviva Holdings Ltd. now owns 1,546,001 shares of the company’s stock valued at $33,328,000 after buying an additional 1,023,501 shares during the last quarter. venBio Select Advisor LLC raised its stake in shares of Mirati Therapeutics by 11.6% in the first quarter. venBio Select Advisor LLC now owns 1,404,055 shares of the company’s stock valued at $30,047,000 after buying an additional 146,000 shares during the last quarter. Macquarie Group Ltd. acquired a new stake in shares of Mirati Therapeutics during the second quarter valued at about $437,000. California State Teachers Retirement System raised its stake in shares of Mirati Therapeutics by 9.5% in the second quarter. California State Teachers Retirement System now owns 26,594 shares of the company’s stock valued at $145,000 after buying an additional 2,300 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC acquired a new stake in shares of Mirati Therapeutics during the second quarter valued at about $165,000. Hedge funds and other institutional investors own 69.49% of the company’s stock.

Mirati Therapeutics (NASDAQ:MRTX) traded down 3.33% during trading on Friday, hitting $5.80. 58,778 shares of the stock were exchanged. Mirati Therapeutics has a 12-month low of $4.40 and a 12-month high of $39.16. The firm’s market capitalization is $115.56 million. The stock has a 50 day moving average price of $5.50 and a 200-day moving average price of $7.63.

About Mirati Therapeutics

5 Day Chart for NASDAQ:MRTX

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.